News
REGN ▼ -1.3% - Regeneron Pharmaceuticals, Inc.
REGN ▼ -1.3% - Regeneron Pharmaceuticals, Inc.
$REGN - Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
18-NOV-2026 06:03 PM ET
Share this post
More filings for $REGN
REGN ▲ +0.1% - Regeneron Pharmaceuticals, Inc.Nov 17, 2026REGN ▲ +0.1% - Regeneron Pharmaceuticals, Inc.Nov 17, 2026REGN ▼ -0.9% - Regeneron Pharmaceuticals, Inc.Nov 12, 2026REGN ▼ -0.3% - Regeneron Pharmaceuticals, Inc.Nov 8, 2026REGN ▲ +3.5% - Regeneron Pharmaceuticals, Inc.Nov 2, 2026REGN ▼ -0.2% - Regeneron Pharmaceuticals, Inc.Nov 2, 2026
View full $REGN filing history →💬 Comments
Loading comments…
Leave a comment
